Sobetirome

Sobetirome
Clinical data

Other names	GC-1
Routes of administration	Oral
Legal status
Legal status	Investigational
Identifiers
IUPAC name 2-[4-[(4-Hydroxy-3-propan-2-ylphenyl)methyl]-3,5-dimethylphenoxy]acetic acid
CAS Number	211110-63-3
PubChem CID	9862248
IUPHAR/BPS	2639
DrugBank	DB07425
ChemSpider	8037944
UNII	XQ31741E9Q
KEGG	D09381
ChEBI	CHEBI:79988
ChEMBL	ChEMBL107400
CompTox Dashboard (EPA)	DTXSID60891557
Chemical and physical data
Formula	C₂₀H₂₄O₄
Molar mass	328.408 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCC(=O)O
InChI InChI=1S/C20H24O4/c1-12(2)17-9-15(5-6-19(17)21)10-18-13(3)7-16(8-14(18)4)24-11-20(22)23/h5-9,12,21H,10-11H2,1-4H3,(H,22,23) Key:QNAZTOHXCZPOSA-UHFFFAOYSA-N

Sobetirome (GC-1) is a thyromimetic drug that binds to the thyroid hormone receptor TRβ1 preferentially compared to TRα1. It has been investigated for the treatment of dyslipidemia, obesity, Pitt–Hopkins syndrome, cholestatic liver disease, multiple sclerosis, bleomycin-induced lung fibrosis, and COVID-19 caused ARDS. It was designated as an orphan drug by the FDA for the treatment of X-linked adrenoleukodystrophy.